C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) C07K 16/24 (2006.01) C07K 16/28 (2006.01) C07K 16/30 (2006.01) C12N 5/12 (2006.01) C12Q 1/02 (2006.01) G01N 33/566 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2485548
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non- cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
L'invention concerne des procédés et des compositions conçus pour le traitement, la gestion ou la prévention du cancer, notamment du cancer métastatique. Les procédés selon l'invention consistent à administrer une quantité efficace d'un ou de plusieurs anticorps se liant à la EphA2 et agonisant celle-ci, augmentant ainsi la phosohorylation de la EphA2 et réduisant les niveaux de la EphA2 dans des cellules dans lesquelles la EphA2 a été agonisée. L'invention concerne également des anticorps se liant de préférence à un épitope de la EphA2 exprimé sur des cellules cancéreuses et pas sur des cellules non cancéreuses. L'invention concerne enfin des compositions pharmaceutiques renfermant un ou plusieurs anticorps de la EphA2 selon l'invention, soit seul, soit conjointement avec un ou plusieurs autres agents utiles pour le traitement du cancer.
Carles-Kinch Kelly
Kinch Michael S.
Stewart Jane C.
Medimmune Inc.
Medimmune Llc
Osler Hoskin & Harcourt Llp
Purdue Research Foundation
LandOfFree
Epha2 agonistic monoclonal antibodies and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epha2 agonistic monoclonal antibodies and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epha2 agonistic monoclonal antibodies and methods of use... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1540414